Pages
- About us
- Accueil
- All events
- Commercial Manufacturing
- Confidentiality Policy
- Contact & Quotation Request
- Contact the Personal Data Protection Officer
- Cosmetic Peptides
- COVID-19 Information
- Custom R&D
- Generic peptides
- Individualized Peptides
- New Products
- Newsletter
- Our Stories
- Personal data
- Quality at PolyPeptide
- Request our Documentation
- Scale and Synthesis strategy
- Services
- Subscribe to PolyPeptide Newsletter
Posts by category
- Category: Articles
- Category: News
- Stock Exchange Listing
- PolyPeptide News Flash, #1, 2021
- PolyPeptide News Flash, #3, 2020
- Press Release: PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine
- PolyPeptide News Flash, #2, 2020
- Information Letter on COVID-19
- New member of the Medicon Valley Alliance
- Category: Non classé
- Information Letter on COVID-19
- PolyPeptide News Flash February 2020
- Innovation and Technology
- PolyPeptide News Flash October
- Press release: the start of a research collaboration program with IBMM in Montpellier, France
- Symposium on Preparative and Process Scale HPLC, MCC and SFC 2019
- Book your meeting with PolyPeptide at CPhI worldwide – Frankfurt, Germany 5-7 November 2019
- 100% Sustainable energy from wind turbines at PolyPeptide Sweden
- PolyPeptide attends TIDES Europe – Amsterdam, November 7th and 8th
- Looking forward to seeing you at CPhI Madrid, 9-11 October, Hall 8, stand #8B2
Generic peptides
- Semaglutide
- Triptorelin
- Somatostatin
- PTH (1-34) Teriparatide
- Octreotide
- Liraglutide
- Leuprolide
- Felypressin
- Desmopressin
- Deslorelin
- Calcitonin
- Atosiban
- Vasopressin, 8-L-Arginine
- Exenatide
- Carbetocin
- ACTH (1-39) Porcine
Events
- CPhI Discover
- TIDES digital week
- Incosmetics Global
- NLSDays - Nordic Life Science
- TIDES Europe
- TIDES US
- CPhI Worldwide
- BIO International Convention San Diego
- CPhI North America
- 7th Annual Peptides & Oligonucleotides Congress
Événements
- MORE THAN 30 APPROVED ACTIVE PHARMACEUTICAL INGREDIENTS
- POLYPEPTIDE GROUP ACQUIRED THE NEW BUSINESS AND OPERATIONS OF LONZA IN BRAINE-L’ALLEUD, BELGIUM
- 22 COMMERCIAL PRODUCTS MANUFACTURED AT POLYPEPTIDE
- ACQUISITION OF A NEW BUILDING IN TORRANCE, USA EXPANSION IN MALMÖ, SWEDEN INAUGURATION OF THE FACILITY IN INDIA
- OPENING OF NEW MANUFACTURING PLANT IN STRASBOURG, FRANCE
- ACQUISITION OF THE NEOMPS GROUP
- START OF CONSTRUCTION OF INDIAN FACILITY NEAR MUMBAI
- ACQUISITION OF WHERL GMBH AND PRAGUE POLYPEPTIDE LABORATORIES SRO.
- OPERATIONS START IN TORRANCE, USA
- FOUNDING OF THE POLYPEPTIDE GROUP IN HILLERØD, DENMARK AND TORRANCE, USA
- START OF COMMERCIAL THERAPEUTIC PEPTIDE MANUFACTURE AT MALMÖ IN SWEDEN